Compare McKesson Corporation (MCK) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Starbucks Corp — how do they compare? McKesson Corporation trades at $886.66 (market cap $105.14B), while Starbucks Corp trades at $108.34 (market cap $121.59B). The key difference: Starbucks Corp is the larger of the two by market cap, and Starbucks Corp pays the higher dividend (2.33%). Which is the better fit depends on your goals.
| MCK | SBUX | |
|---|---|---|
Market Cap | $105.14B | $121.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $108.37 |
52-Week Low | $659.01 | $78.46 |
Enterprise Value | $111.67B | $140.42B |
Dividend Yield | 0.42% | 2.33% |
Volume | — | 7,493,833 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $879.87, up 1.18% today, with strong momentum from recent earnings beats and raised guidance. The stock shows bullish technical signals, supported by robust revenue growth and solid cash flow generation. Recent news highlights strength in specialty drugs and oncology, driving positive sentiment.
Outlook remains favorable with a consensus price target of $990.67, though thin profit margins and high liabilities pose risks. Continued execution on growth initiatives and cost discipline are key for sustained upside, while macroeconomic pressures and competitive dynamics require monitoring.
Starbucks (SBUX) trades at $107.57, up 2.79% today, showing strong momentum near its 52-week high. The stock benefits from a bullish technical outlook and improved quarterly earnings, with Q2 2026 EPS beating estimates at $0.85 vs. $0.66 expected. Revenue trends are positive, with 2025 revenue reaching $37.18B, though net income margin declined to 5.17%. Recent news highlights a turnaround in traffic and margin expansion, supported by new product launches like carbonated refreshers and seasonal offerings.
The outlook for SBUX is cautiously optimistic, with analyst consensus pointing to a $113.60 price target. Key opportunities include sustained traffic recovery and cost efficiency gains, but risks remain from high valuation (P/E 61.65) and competitive pressures. Investors should weigh the earnings rebound against premium multiples and monitor execution of growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
